Literature DB >> 23479628

Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas.

Naohiko Ikegaki1, Hiroyuki Shimada, Autumn M Fox, Paul L Regan, Joshua R Jacobs, Sakeenah L Hicks, Eric F Rappaport, Xao X Tang.   

Abstract

Cancer stem cells (CSCs) are plastic in nature, a characteristic that hampers cancer therapeutics. Neuroblastoma (NB) is a pediatric tumor of neural crest origin, and half of the cases are highly aggressive. By treating NB cell lines [SKNAS, SKNBE(2)C, CHP134, and SY5Y] with epigenetic modifiers for a short time, followed by sphere-forming culture conditions, we have established stem cell-like NB cells that are phenotypically stable for more than a year. These cells are characterized by their high expression of stemness factors, stem cell markers, and open chromatin structure. We referred to these cells as induced CSCs (iCSCs). SKNAS iCSC and SKNBE(2)C iCSC clones (as few as 100 cells) injected s.c. into SCID/Beige mice formed tumors, and in one case, SKNBE(2)C iCSCs metastasized to the adrenal gland, suggesting their increased metastatic potential. SKNAS iCSC xenografts showed the histologic appearance of totally undifferentiated large-cell NBs (LCNs), the most aggressive and deadly form of NB in humans. Immunohistochemical analyses showed that SKNAS iCSC xenografts expressed high levels of the stem cell marker CXCR4, whereas the SKNAS monolayer cell xenografts did not. The patterns of CXCR4 and MYC expression in SKNAS iCSC xenografts resembled those in the LCNs. The xenografts established from the NB iCSCs shared two common features: the LCN phenotype and high-level MYC/MYCN expression. These observations suggest both that NB cells with large and vesicular nuclei, representing their open chromatin structure, are indicative of stem cell-like tumor cells and that epigenetic changes may have contributed to the development of these most malignant NB cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23479628      PMCID: PMC3625318          DOI: 10.1073/pnas.1118262110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  SOX9 induces and maintains neural stem cells.

Authors:  Charlotte E Scott; Sarah L Wynn; Abdul Sesay; Catarina Cruz; Martin Cheung; Maria-Victoria Gomez Gaviro; Sarah Booth; Bo Gao; Kathryn S E Cheah; Robin Lovell-Badge; James Briscoe
Journal:  Nat Neurosci       Date:  2010-10       Impact factor: 24.884

2.  Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.

Authors:  Paul L Regan; Joshua Jacobs; Gerald Wang; Jaime Torres; Robby Edo; Jennifer Friedmann; Xao X Tang
Journal:  Int J Oncol       Date:  2011-01       Impact factor: 5.650

Review 3.  Pathology of peripheral neuroblastic tumors: significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma.

Authors:  Tamás Tornóczky; Dávid Semjén; Hiroyuki Shimada; Inge M Ambros
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

4.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Authors:  Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

5.  Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.

Authors:  J I Johnsen; L Segerström; A Orrego; L Elfman; M Henriksson; B Kågedal; S Eksborg; B Sveinbjörnsson; P Kogner
Journal:  Oncogene       Date:  2007-11-19       Impact factor: 9.867

6.  Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival.

Authors:  Aurélie Ernst; Stefanie Hofmann; Rezvan Ahmadi; Natalia Becker; Andrey Korshunov; Felix Engel; Christian Hartmann; Jörg Felsberg; Michael Sabel; Heike Peterziel; Moritz Durchdewald; Jochen Hess; Sebastian Barbus; Benito Campos; Anna Starzinski-Powitz; Andreas Unterberg; Guido Reifenberger; Peter Lichter; Christel Herold-Mende; Bernhard Radlwimmer
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

7.  Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.

Authors:  Claire Marie-Elisabeth Sauvageot; Jessica Leigh Weatherbee; Santosh Kesari; Susan Elizabeth Winters; Jessica Barnes; Jamie Dellagatta; Naren Raj Ramakrishna; Charles Dean Stiles; Andrew Li-Jen Kung; Mark W Kieran; Patrick Yung Chih Wen
Journal:  Neuro Oncol       Date:  2008-08-05       Impact factor: 12.300

8.  Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells.

Authors:  Tobias Brambrink; Ruth Foreman; G Grant Welstead; Christopher J Lengner; Marius Wernig; Heikyung Suh; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2008-02-07       Impact factor: 24.633

9.  Identification of selective inhibitors of cancer stem cells by high-throughput screening.

Authors:  Piyush B Gupta; Tamer T Onder; Robert A Weinberg; Eric S Lander; Guozhi Jiang; Kai Tao; Charlotte Kuperwasser
Journal:  Cell       Date:  2009-08-13       Impact factor: 41.582

10.  Chd1 regulates open chromatin and pluripotency of embryonic stem cells.

Authors:  Alexandre Gaspar-Maia; Adi Alajem; Fanny Polesso; Rupa Sridharan; Mike J Mason; Amy Heidersbach; João Ramalho-Santos; Michael T McManus; Kathrin Plath; Eran Meshorer; Miguel Ramalho-Santos
Journal:  Nature       Date:  2009-07-08       Impact factor: 49.962

View more
  22 in total

1.  Ossifying fibroma tumor stem cells are maintained by epigenetic regulation of a TSP1/TGF-β/SMAD3 autocrine loop.

Authors:  Haiyan Qin; Cunye Qu; Takayoshi Yamaza; Ruili Yang; Xia Lin; Xue-Yan Duan; Kentaro Akiyama; Yi Liu; Qunzhou Zhang; Chider Chen; Yibu Chen; Hank Heng Qi; Xin-Hua Feng; Anh D Le; Songtao Shi
Journal:  Cell Stem Cell       Date:  2013-11-07       Impact factor: 24.633

Review 2.  Chemotherapy targeting cancer stem cells.

Authors:  Haiguang Liu; Lin Lv; Kai Yang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 3.  Common stemness regulators of embryonic and cancer stem cells.

Authors:  Christiana Hadjimichael; Konstantina Chanoumidou; Natalia Papadopoulou; Panagiota Arampatzi; Joseph Papamatheakis; Androniki Kretsovali
Journal:  World J Stem Cells       Date:  2015-10-26       Impact factor: 5.326

4.  Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma.

Authors:  Jordan S Taylor; Burcin Yavuz; Jasmine Zeki; Lauren Wood; Naohiko Ikegaki; Jeannine Coburn; Kristin Harrington; Hiroyuki Shimada; David L Kaplan; Bill Chiu
Journal:  Surgery       Date:  2020-02-28       Impact factor: 3.982

5.  Replicating and identifying large cell neuroblastoma using high-dose intra-tumoral chemotherapy and automated digital analysis.

Authors:  Jordan S Taylor; Lingdao Sha; Naohiko Ikegaki; Jasmine Zeki; Ryan Deaton; Jamie Harris; Jeannine Coburn; Burcin Yavuz; Amit Sethi; Hiroyuki Shimada; David L Kaplan; Peter Gann; Bill Chiu
Journal:  J Pediatr Surg       Date:  2019-08-31       Impact factor: 2.545

6.  Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma.

Authors:  Melanie A Krook; Lauren A Nicholls; Christopher A Scannell; Rashmi Chugh; Dafydd G Thomas; Elizabeth R Lawlor
Journal:  Mol Cancer Res       Date:  2014-03-20       Impact factor: 5.852

7.  Downregulation of c-Myc is involved in TLR3-mediated tumor death of neuroblastoma xenografts.

Authors:  Li-Ling Lin; Chao-Cheng Huang; Chia-Ling Wu; Min-Tsui Wu; Wen-Ming Hsu; Jiin-Haur Chuang
Journal:  Lab Invest       Date:  2016-05-16       Impact factor: 5.662

Review 8.  Biomaterial-based platforms for cancer stem cell enrichment and study.

Authors:  Chunhua Luo; Zhongjie Ding; Yun Tu; Jiao Tan; Qing Luo; Guanbin Song
Journal:  Cancer Biol Med       Date:  2021-03-19       Impact factor: 4.248

9.  Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenografts.

Authors:  Raoud Marayati; Laura V Bownes; Colin H Quinn; Nikita Wadhwani; Adele P Williams; Hooper R Markert; Venkatram Atigadda; Jamie M Aye; Jerry E Stewart; Karina J Yoon; Elizabeth A Beierle
Journal:  J Pediatr Surg       Date:  2021-02-24       Impact factor: 2.549

10.  S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines.

Authors:  Naohiko Ikegaki; Sakeenah L Hicks; Paul L Regan; Joshua Jacobs; Amina S Jumbo; Payton Leonhardt; Eric F Rappaport; Xao X Tang
Journal:  Int J Oncol       Date:  2013-10-25       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.